NewAmsterdam Pharma COO Douglas Kling to Resign
NewAmsterdam Pharma Company N.V. announced that Chief Operating Officer Douglas Kling notified the company on July 16, 2026 that he will resign, with his departure effective August 14, 2026.
Rhea-AI Filing Summary
NewAmsterdam Pharma Company N.V. announced that Chief Operating Officer Douglas Kling notified the company on July 16, 2026 that he will resign, with his departure effective August 14, 2026. He is leaving to become chief executive officer of another clinical-stage biotech company.
The company expects to enter into a separation agreement with Mr. Kling and an advisor agreement under which he would provide transition and advisory services for the PREVAIL clinical trial of obicetrapib and other clinical programs. Material terms of these agreements are expected to be disclosed later.
Positive
- None.
Negative
- Chief Operating Officer departure: Douglas Kling will resign as COO effective August 14, 2026 to become a CEO elsewhere, resulting in a senior leadership transition at NewAmsterdam Pharma.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation notice date: July 16, 2026
COO resignation effective date: August 14, 2026
Nominal value per ordinary share: €0.12 per share
3 metrics
Resignation notice date
July 16, 2026
Date Douglas Kling notified NewAmsterdam Pharma of his resignation as COO
COO resignation effective date
August 14, 2026
Effective date of Douglas Kling’s resignation as Chief Operating Officer
Nominal value per ordinary share
€0.12 per share
Nominal value of NewAmsterdam Pharma ordinary shares listed on The Nasdaq Stock Market LLC
Key Terms
separation agreement, advisor agreement, PREVAIL clinical trial, clinical-stage biotech company
4 terms
separation agreement regulatory
"expects to enter into a separation agreement in connection with Mr. Kling’s departure"
A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.
advisor agreement regulatory
"expects to enter into an advisor agreement with Mr. Kling pursuant to which he will provide"
PREVAIL clinical trial medical
"services related to the Company’s PREVAIL clinical trial of obicetrapib and other clinical programs"
clinical-stage biotech company medical
"to be appointed as the chief executive officer of another clinical-stage biotech company"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive change did NewAmsterdam Pharma (NAMS) disclose?
NewAmsterdam Pharma disclosed that Chief Operating Officer Douglas Kling will resign. He notified the company on July 16, 2026, and his resignation becomes effective on August 14, 2026, when he will leave to lead another clinical-stage biotech company.
When will NewAmsterdam Pharma (NAMS) COO Douglas Kling’s resignation take effect?
Douglas Kling’s resignation as Chief Operating Officer takes effect on August 14, 2026. He informed NewAmsterdam Pharma of his decision on July 16, 2026, providing a transition period before moving to a chief executive officer role elsewhere.
Why is NewAmsterdam Pharma (NAMS) COO Douglas Kling leaving the company?
Douglas Kling is resigning as COO to become the chief executive officer of another clinical-stage biotech company. NewAmsterdam Pharma indicated this career move as the reason for his departure, while planning to keep him involved in a transition capacity.
Will Douglas Kling continue working with NewAmsterdam Pharma (NAMS) after his resignation?
NewAmsterdam Pharma expects to enter into an advisor agreement with Douglas Kling. Under this arrangement, he would provide transition and advisory services related to the PREVAIL clinical trial of obicetrapib and other clinical programs, subject to mutual agreement on terms.
What agreements does NewAmsterdam Pharma (NAMS) plan in connection with the COO’s departure?
The company expects both a separation agreement and an advisor agreement with Douglas Kling. The separation agreement will govern his departure, while the advisor agreement would cover his transition and advisory work. Material terms are expected to be disclosed in a later amendment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
